The Roles of DEA and FDA in the Cannabis Legalization Process

Stanley Jutkowitz, Senior Counsel with Seyfarth Shaw LLP discusses the recent DEA decision to reschedule cannabis from schedule one to schedule three, with potential less restrictive schedules. Stanley provided legal insights on the implications of this move, while highlighting the controversy surrounding cannabis legalization and rescheduling. We also explored the roles of DEA and FDA in the legalization process, emphasizing the complexity of the legal landscape with multiple agencies involved and conflicting treaty obligations and federal laws. We also discussed regulatory challenges and legal implications of cannabis, including the distinction between hemp and marijuana, taxation and decriminalization, and the current state of legalization and regulation in the US.